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ABSTRACT: Introduction: Andersen–Tawil syndrome (ATS) is a
potassium channelopathy affecting cardiac and skeletal muscle.
Periodic paralysis is a presenting symptom in some patients,
whereas, in others, symptomatic arrhythmias or prolongation of
QT in echocardiographic recordings will lead to diagnosis of
ATS. Striking intrafamilial variability of expression of KCNJ2
mutations and rarity of the syndrome may lead to misdiagnosis.
Methods: We report 15 patients from 8 Polish families with ATS,
including 3 with novel KCNJ2 mutations. Results: All patients
had dysmorphic features; periodic paralysis affected males
more frequently than females (80% vs. 20%), and most attacks
were normokalemic. Two patients (with T75M and T309I muta-
tions) had aborted sudden cardiac death. An implantable
cardioverter-defibrillator was utilized in 40% of cases. Conclu-
sions: KCNJ2 mutations cause a variable phenotype, with dys-
morphic features seen in all patients studied, a high penetrance
of periodic paralysis in males and ventricular arrhythmia with a
risk of sudden cardiac death.
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Andersen–Tawil syndrome [ATS; Online Mende-
lian Inheritance in Man (OMIM) 170390, http://
omim.org/entry/170390; Orphanet (European
website providing information about orphan drugs
and rare diseases) number: ORPHA37553] is an
autosomal dominant potassium channelopathy
caused by mutations of the KCNJ2 gene on chro-
mosome 17.1 KCNJ2 encodes the a-subunit of the
inward-rectifier potassium channel Kir2.1 and is
expressed in both skeletal and cardiac muscle.
KCNJ2 mutations have been shown to cause
dominant-negative suppression of channel func-
tion.2 Clinically, this leads to periodic paralysis
(PP) and polymorphic ventricular arrhythmias
and/or echocardiographic (ECG) abnormalities
with a prolonged corrected QT (QTc) interval and
a distinct U wave with long QTU interval. Most
patients also have dysmorphic features, such as
hypertelorism, small chin, cleft palate, clindactyly,
syndactyly, or short stature.2–6 ATS symptoms vary
even within families. Mutations are highly pene-
trant, but expression is quite variable. The pheno-
typic variability and rarity of ATS make it
challenging to diagnose. The disease is rare, with
an estimated prevalence of 1 case per 1,000,000
population (approximately 38 cases in Poland). In
England, the prevalence of genetically confirmed
ATS is 0.08 per 100,000.7 We describe the geno-
type–phenotype characteristics of 15 patients from
8 unrelated families with genetically confirmed
ATS, including 3 with novel mutations.
METHODS
We performed a retrospective analysis of medi-
cal records of 15 Caucasian subjects (10 females
and 5 males) from 8 unrelated families seen at a
single neurological department during the period
from January 1, 2003 through March 30, 2013. All
probands were children and met the diagnostic cri-
teria for ATS.2–5 The mother in the family (num-
ber 6), with a history of cardiac arrhythmia, was
not available for clinical and genetic studies. All
subjects participated in the study after giving
informed consent. The investigation was approved
by the ethics committee at the Medical University
of Warsaw (AKBE/80/13). Clinical evaluation
included family and medical history, with review of
previous medical records if applicable. Neurologi-
cal and general physical examinations were per-
formed. Serum electrolytes, both during PP
episodes and interictally, and thyroid hormone
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tests were performed. PP was diagnosed based on a
history of documented flaccid paralysis episodes or
an abnormal result on an electrophysiological long
exercise test, as described by McManis et al.8 All
subjects underwent standard 12-lead electrocardi-
ography (ECG) and ambulatory 24-hour Holter
monitoring, which was performed during normal
activity with 3-channel digitized recorders (Lifecard
CF; Sentinel, USA). An evaluation of heart rate
and presence of ventricular and supraventricular
arrhythmias was performed (Impresario; Sentinel).
Special attention was paid to the presence of ven-
tricular premature beats (VPBs), ventricular cou-
plets, and ventricular tachycardia (VT), especially
when bidirectional (BVT) or polymorphic. Diagno-
sis of ventricular arrhythmias followed ACC/AHA/
ESC 2006 guidelines for management of patients
with ventricular arrhythmias and the prevention of
sudden cardiac death.9
During ECG and 24-hour Holter analysis, QT
and QTc intervals were assessed with the Bazett
formula. When a distinct U wave was present, QTU
and corrected QTU (QTUc) intervals were also
measured. According to current standards of ECG
assessment, a QTc interval 450 ms in males and
460 ms in females is regarded as abnormal.10 In
all subjects, significant structural heart abnormal-
ities were excluded with transthoracic
echocardiography.
DNA Mutation Analysis. Genomic DNA was isolated
from leukocyte nuclei using a standard procedure.
Family numbers 1–5 were tested by L.P., numbers
and 6 and 7 by R.P., and number 8 by K.Sz.
Genetic screening for KCNJ2 was performed by
polymerase chain reaction and sequencing as
reported previously.1
RESULTS
Table 1 lists the clinical findings and mutations
of the ATS patients studied. Eight different KCNJ2
mutations were found, and 3 of them are novel:
c.155G>T (G52V); c.412G>A (E138K); and
c.436G>C (G146R). They were considered causal
Table 1. Clinical characteristics of ATS patients.
Patient
Mutation
KCNJ2
Age at
Dx (y)
Age (y) of
first symptoms PP (onset)
Cardiac manifestation
onset
Maximum QTc/QTUc
ms24-h ECG monitoring
1-1F G146R 10 7 (PP) Yes (7 y) Asymptomatic (8 y) QTc5 420, QTUc5 710,
VPBs 6637, nsBVT 5
1–2F G146R 36 In teens No Syncope in teens QTc5 450, VPB 1
2-1M E138K
de novo
5.5 In utero
(arrhythmia)
Yes (1 y) Asymptomatic QTc5 400 QTUc5540,
VPBs 63, nsVT(–)
3-1M T75M 13 12 (PP) Yes (12 y) Arrhythmia, syncope,
after ICD asymptomatic
QTc5 445, QTUc5 640,
VPBs 40,000,
nsBDT 604
3-2F T75M 37 19, arrhythmia No Survived SCD,ICD
at age 33 y
Data unavailable
4-1F D71V 16 12, arrhythmia No Asymptomatic QTc5 380, QTUc5 650,
VPBs 2600,
BVT frequent
4-2M D71V 44 15, (PP) Yes
(15 y)
Asymptomatic QTc5 470 QTUc5650,
VPBs 56, nsVT(–)
5-1M T309I 18 13, cardiac Yes
(13.5 y)
Cardiac arrest/ICD
(13 y)
QTc5 350, QTUc5 580,
VPBs 5% of TDB
5-2F T309I 40 Asymptomatic No Asymptomatic QTc5 460, QTU5 660
5-3F T309I 20 10 cardiac No Syncope, ICD (10 y) QTc5 400, QTUc5 640,
VPBs 4.5% of TDB
5-4F T309I 65 No data No Arrhythmia Not available
6-1F R82W 17 7, arrhythmia No Syncope/ICD at 14 y QTc5 380, QTUc5 610,
VPBs 15,290,
nsVT 40
7-1F R82Q 15 12, arrhythmia No Syncope/ICD at 12 y QTc5 430 QTUc5700,
VPBs 15% of TDB,
sporadic nsBVT,
7-2M R82Q 40 Teens, arrhythmia No Syncope in teens QTc5 460 during sotalol
therapy for Wolff–Parkinson–
White syndrome
8-1F G52V
de novo
13.5 7 (PP) Yes Asymptomatic, long QT
during arechin treatment
QTc5 450, QTUc5 640,
VPBs 6988, nsBVT 10
Age expressed in years (y). Dx, diagnosis; PP, periodic paralysis; ECG, electrocardiography; ICD, implantable cardioverter-defibrillator; VPB, ventricular pre-
mature beat; BVT, bidirectional ventricular tachycardia; SCD, sudden cardiac death.
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for ATS, because they were not found in the
dbSNP and National Heart, Lung, and Blood
Institute (NHLBI) Exome Sequencing Project
databases, and they segregated by clinical pheno-
type in the tested families.
In 5 families we were able to document ATS in
more than 1 family member (Table 1). There were
2 de-novo mutations, including a boy with a severe
ATS phenotype (see case description below). In 1
family, the mother, with a history of cardiac
arrhythmia, was not available for testing. In the
probands, the time from first symptom to ATS
diagnosis ranged from 1 to 10 years (mean 4.7
years). The testing led to ATS diagnosis in the
remaining family members.
Case Description. The boy (patient 2-1) with an
E138K de-novo mutation had a severe, early-onset
clinical presentation. He was first seen in the Neu-
rology Department at the age of 5.5 years for a
diagnosis of recurrent episodes of flaccid paralysis
lasting from hours to 1 week. His psychomotor
milestones were normal, and he started walking
unsupported at age 11 months. PP episodes were
observed since he was age 13 months; their fre-
quency ranged from 4–6 per month to once every
2 months. During most episodes he was not able
to stand or walk unsupported, but between epi-
sodes his muscle strength was normal. He had a
history of cardiac dysrhythmia first observed on
cardiac monitoring before and during labor. When
he was age 2 years, arrhythmia was observed during
treatment with an over-the-counter drug contain-
ing pseudoephedrine. His mother was treated for
epilepsy in her childhood, but she did not have
the KCNJ2 mutation. Otherwise, his family history
was not relevant. On admission he presented with
short stature (103 cm, below the 3rd percentile for
age), hypertelorism, small chin, clindactyly of the
fifth toe, and syndactyly of the second and third
toes. During hospitalization, a normokalemic peri-
odic paralysis episode lasting 1 day was observed.
During this episode the boy could not ambulate. A
McManis test performed during an interictal
period demonstrated abnormal muscle membrane
excitability after exercise, with a 58.6% decrement
in compound muscle action potential amplitude
after exercise, further confirming the diagnosis.
This patient’s cardiac abnormalities are presented
in Table 1.
Periodic Paralysis. PP episodes were observed in 7
patients from 6 kinships, with 5 of them male.
Eight female patients had an isolated cardiac phe-
notype. Only 1 patient presented with no family
history of skeletal muscle involvement (the girl’s
mother is affected with arrhythmia by history). PP
episodes were normokalemic in all families stud-
ied; only 1 subject (4-2) was documented to have
both normo- and hypokalemic PP. Episodes lasted
from 1 hour to over 1 week, always with marked
improvement. Only 1 patient (1-1) had residual
weakness between episodes. In all patients affected
with PP, treatment with acetazolamide led to sub-
jective improvement in paralysis severity and dura-
tion, but none became PP free.
Cardiac Manifestations. QTc Interval and U
Wave. A normal QTc interval was present in 10 of
13 (76.9%) subjects, whereas a prolonged QTc
interval was present in only 3, in 1 of whom it was
recorded during sotatol therapy administered due
to previously diagnosed typical Wolff–Parkinson–
White syndrome (QTc 460 ms). This patient
refused electrophysiological study. After the ATS
diagnosis, sotalol therapy was continued, and no
significant arrhythmia was observed. In another
fully asymptomatic 15-year-old boy, the QTc was
470 ms, and no significant ventricular arrhythmia
was found during Holter monitoring. In the third
case, an asymptomatic female, the QTc was 460
ms. Prominent U waves were observed in 11 of 13
(84.6%) subjects.
Ventricular Arrhythmia. No, or insignificant
ventricular arrhythmia, defined by sporadic VPBs
only, was recorded in 4 of 12 patients in whom
Holter monitoring was performed. The most fre-
quent form of complex ventricular arrhythmia was
BVT or bidirectional couplets, detected in 6 of 12
patients. Monomorphic, non-sustained VT, or fre-
quent VPBs without BVT, were found in 2 patients
only. All patients with ventricular arrhythmias
received b blockers, most frequently bisoprolol.
Two of 15 (13%) patients survived cardiac
arrest, with subsequent implantable cardioverter-
defibrillator (ICD) utilized for secondary preven-
tion. An ICD was also implanted in another
4 patients for primary sudden cardiac death
(SCD) prevention. All patients had recurrent syn-
cope and episodes of BVT with Holter monitor-
ing. Altogether, an ICD was implanted in 40% of
patients. In all, QTc measurements were within
the normal range (Table 1). In addition, as men-
tioned in the case description, arrhythmia was
diagnosed in utero, but no complex arrhythmia
was observed subsequently; this patient is cur-
rently asymptomatic. Only 3 (25%) of 12 patients
are clinically and electrocardiographically (Holter
monitoring) asymptomatic.
Dysmorphic features were seen in all of our
subjects. Mild hypertelorism and a small, triangular
chin was observed in all probands and mutation
carriers. A severely short stature was seen in patient
2-1, and a cleft palate was observed in patient 1-1.
Most had clindactyly/syndactyly. None of the
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subjects had congenital heart anomalies or renal
malformations.
DISCUSSION
To date, over 40 different mutations and 3
small deletions of KCNJ2 have been reported.
There were 8 different heterozygous KCNJ2 muta-
tions in our study. Five were reported previously:
c.224C>T (T75M)11,12; c.212A>T (D71V)1;
c.926C>T (T309I)13; c.244C>T (R82W)14; and
c.245G>A (R82Q).12 We identified 3 novel KCNJ2
mutations: c.155G>T (G52V); c.412G>A (E138K);
and c.436G>C (G146R), including 2 de-novo muta-
tions. They were found in probands who expressed
all 3 typical ATS clinical features: dysmorphia; nor-
mokalemic PP; and cardiac arrhythmia.1,3,4,15 The
E138K mutation caused a severe phenotype with
asymptomatic arrhythmia in utero, a finding not
previously reported in ATS. In the remaining 2
probands with novel mutations, PP was a dominant
clinical feature, although subclinical arrhythmia
was also present. The patient with the T309I muta-
tion had a history of aborted cardiac arrest at age
13 years and a family history suggestive of SCD in
a maternal uncle. In all but 1 family, 3 ATS fea-
tures could be documented, with variability
between and within families.6,15 We observed PP
attacks in 20% of females and 80% of males. A his-
tory of syncope or cardiac arrest occurred in 50%
of females and 60% of males. In a previously
reported large kindred with the R67W mutation,
ventricular arrhythmias segregated with females
(13 of 16 studied, 81%), whereas PP was observed
in 10 of 25 (40%) male mutation carriers.16
Reduced expressivity of mutations and lower attack
frequency in women than in men with PP is also a
feature of hypokalemic PP caused by CACNA1S
and SCN4A mutations.17 The exact mechanism of
such gender specificity of PP episodes in ATS has
not been elucidated.
Studies have shown that estrogen exerts a
strong effect on Kv4.3 potassium channel expres-
sion.18 Hormonal influences on Kir2.1 function
mediated by a corticoid signaling pathway were
also demonstrated.19 We were not able to perform
physiological studies to identify the nature of the
alteration in channel function caused by the novel
KCJ2 mutations. Previous studies demonstrated
that the ATS phenotype may occur as a result of a
defect in trafficking and conductance of the
inward-rectifier K1 channel.20 Dysfunction of the
skeletal muscle inward-rectifier K1 channels also
leads to depolarization-induced paralysis in hypo-
kalemic periodic paralysis caused by calcium chan-
nel mutations (CACNL1A3) and in thyrotoxic
PP.21,22 In CACNL1A3 mutations the paradoxical
depolarization in low K1 is not prevented by the
CaV1.1 blocker nitrendipine. The membrane cur-
rent–voltage relationship mostly reflects the activity
of K1 channels.22 The cardiac phenotype was
highly variable in our patients. The clinical spec-
trum included clinically and electrocardiographi-
cally asymptomatic subjects (25% of observed
cases) and also 2 SCD survivors. Although only a
few cases of sudden cardiac death in ATS have
been reported previously,23 a 45-year-old uncle of
our proband had fatal SCD. ICDs were implanted
in 2 SCD survivors and in another 4 of our patients
with recurrent syncope and complex ventricular
arrhythmia for primary SCD prevention.
Although ATS is classified as a long QT7 syn-
drome (LQT7),2 our data are consistent with
previous observations and showed a normal QTc
interval in 76% of patients studied. However, in
accordance with a published ECG study, which
reported no QT prolongation but an abnormal
T–U-wave pattern,24 we observed prominent U
waves in standard ECGs of 84% of patients.
Importantly, the majority of patients (approxi-
mately 75%) had ventricular arrhythmia, which
corresponds to recent studies reporting ventricu-
lar arrhythmia in 80% of cases.25 Interestingly,
BVT was a typical complex arrhythmia in our
subjects.
In conclusion, the reported KCNJ2 mutations
demonstrated a variable phenotype. We found dys-
morphic features in all of our patients, a high pen-
etrance of PP in males, and polymorphic
ventricular tachycardia with a risk of SCD.
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